Birke; Franz

Patent Applications and Registrations

Patent applications and USPTO patent grants for Birke; Franz.The latest application filed is for "1-phenyl-1,2-diaminoethane derivatives as modulators of the chemokine receptor activity".

Company Profile

0.9.14

Birke; Franz - Waldalgesheim DE
Birke; Franz - Ingelheim DE
Birke; Franz - Ingelheim Rhein DE
Birke; Franz - Ingelheim am Rhein DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Alkyl-and piperidine-substituted benzimidazole derivatives Grant 7,723,360 - Anderskewitz , et al. May 25, 2	2010-05-25
Piperidine-substituted indoles-or heteroderivatives thereof Grant 7,544,806 - Anderskewitz , et al. June 9, 2	2009-06-09
1-Phenyl-1,2-Diaminoethane Derivatives As Modulators Of The Chemokine Receptor Activity App 20080171749 - DOLLINGER; Horst ; et al.	2008-07-17
Pyrrolidinohydrochinazolines Grant 7,214,703 - Anderskewitz , et al. May 8, 2	2007-05-08
Haloalkyl- and piperidine-substituted benzimidazole-derivatives Grant 7,157,471 - Anderskewitz , et al. January 2, 2	2007-01-02
Alkyl-and piperidine-substituted benzimidazole derivatives App 20060030590 - Anderskewitz; Ralf ; et al.	2006-02-09
Use of LTB4 antagonists in veterinary medicine Grant 6,921,752 - Birke , et al. July 26, 2	2005-07-26
Novel piperidine-substituted indoles-or heteroderivatives thereof App 20050153979 - Anderskewitz, Ralf ; et al.	2005-07-14
Haloalkyl- and piperidine-substituted benzimidazole-derivatives App 20050124659 - Anderskewitz, Ralf ; et al.	2005-06-09
Pyrrolidinohydrochinazolines App 20050027122 - Anderskewitz, Ralf ; et al.	2005-02-03
Novel n-(heterobicycloalkanes)-substituted indoles-or heteroderivatives thereof App 20050014782 - Anderskewitz, Ralf ; et al.	2005-01-20
Pharmaceutical composition App 20040116516 - Birke, Franz ; et al.	2004-06-17
1-Phenyl-1,2-diaminoethane derivatives as modulators of the chemokine receptor activity App 20040063779 - Dollinger, Horst ; et al.	2004-04-01
Use of LTB4 antagonists in veterinary medicine App 20030225004 - Birke, Franz ; et al.	2003-12-04
Compositions and methods for treating cystic fibrosis App 20030181518 - Anderskewitz, Ralf ; et al.	2003-09-25
Amidine derivatives, the preparation and use thereof as medicaments with LTB4 antagonistic effect App 20030130232 - Anderskewitz, Ralf ; et al.	2003-07-10
Sulphoxybenzamides App 20020161043 - Anderskewitz, Ralf ; et al.	2002-10-31
Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes App 20020137792 - Anderskewitz, Ralf ; et al.	2002-09-26
Pyranoside derivatives App 20020128209 - Anderskewitz, Ralf ; et al.	2002-09-12
Acylamino-substituted hetrazepines Grant 5,753,647 - Weber , et al. May 19, 1	1998-05-19
Substituted benzamidine compounds which have useful pharmaceutical activity Grant 5,731,332 - Anderskewitz , et al. March 24, 1	1998-03-24
Hetrazepinoid amides Grant 5,698,552 - Weber , et al. December 16, 1	1997-12-16
New diazepines substituted in the 6-position, processes for their preparation and their use as pharmaceutical compositions Grant 5,185,442 - Weber , et al. February 9, 1	1993-02-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.